In Mozambique, HIV prevalence among children aged one to four years old was 1.4 per cent in 2009. The challenge of long-term adherence in adults as well as children during HIV treatment can be associated with the emergence of drug-resistant viruses resulting in treatment failure. Understanding the pattern of primary drug resistance and the impact of maternal and neonatal prophylaxis to define correct HIV treatment regimens is crucial. The main aims of this study are to describe the emergence of primary drug resistance among HIV infected children, the impact of maternal and nenatal prophylaxis associated with the emergence of drug resistance mutations, and the molecular epidemiology of HIV among these children. Retrospectively, dried blood spot (DBS) samples collected from HIV positive children used for routine HIV diagnosis using DNA PCR in four different laboratories in Mozambique were selected. DNA was extracted from DBS samples and used for genotyping. Drug resistance mutations and subtype distribution were analyzed by Stanford resistance algorithms. The relationship between drug resistance mutations to nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTI and NNRTI) and maternal/neonatal prophylaxis was performed by regression models. In total, 496 DBS were collected and 429 (86.5 per cent) were successfully genotyped: HIV-1 subtype C was the most prevalent (97 per cent), followed by subtype A1 (1.2 per cent), mosaic recombinant forms (1.2 per cent), subtype G (0.5 per cent), and subtype D (0.2 per cent). Over 60 per cent of the children had at least one mutation associated to drug resistance to NRTI/NNRTI. As expected a high frequency of mutations to NNRT (52.9 per cent) in comparison to NRTIs (11.4 per cent) due to the low genetic barrier of this class of drugs was observed. For NNRTI, K103N, Y181C, E138A, and G190A were most common whereas for the NRTI, M184V was the most common. Maternal prophylaxis with HAART was significantly (P \< 0.05, OR 2.41) associated with the emergence of drug resistance mutation to NRTI in HIV infected children. In conclusion, the high level of transmitted-resistant viruses observed in this study suggests that political strategies to enhance the level of adherence in maternal HAART should be taken into account. This is an important consideration due to the fact that Mozambique recently implemented the integrated PMTCT option B+ approach. Low adherence in such a treatment context may undermine de efficacy of first-line option in the country. Continuing surveillance studies among HIV infected children remains critical to monitor the impact of PMTCT strategies. Furthermore, current results highlight the need to reinforce adherence counseling with appropriate follow up.
